Stifel analyst Jonathan Block lowered the firm’s price target on Idexx Laboratories (IDXX) to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view Idexx as more of a second half story, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories management to meet with Piper Sandler
- Idexx Laboratories Announces Executive Departure Amid Strategic Realignment
- Top Hedge Fund Manager Sounds the Alarm on Market Risk. Here Are 4 Ways to Play a Possible Selloff
- TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
- Idexx Laboratories Announces Director Retirement and Board Changes